Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2012

Open Access 01-12-2012 | Case report

Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review

Authors: Roberto Ochoa, Pablo A Bejarano, Stefan Glück, Alberto J Montero

Published in: Journal of Medical Case Reports | Issue 1/2012

Login to get access

Abstract

Introduction

Pulmonary toxicities associated with chemotherapeutic agents utilized as adjuvant therapy in patients with breast cancer are distinctly uncommon. The chemotherapy regimen of docetaxel/cyclophosphamide has a more favorable therapeutic index compared to anthracycline-based regimens due to a significantly lower incidence of heart failure and leukemia. Consequently, docetaxel/cyclophosphamide is the preferred adjuvant chemotherapy of choice in older women or in women where anthracyclines may be contraindicated. Pulmonary complications in patients with breast cancer receiving taxane-based adjuvant chemotherapy in the absence of radiation are distinctly uncommon. Here, we report the case of a patient receiving adjuvant docetaxel/cyclophosphamide who developed rapid-onset, biopsy-proven interstitial pneumonitis.

Case presentation

A 72-year-old Hispanic woman was diagnosed as having stage 3 hormone-receptor positive, human epidermal growth factor receptor 2/neu negative, invasive breast cancer. Due to the estimated 10-year risk of recurrence of approximately 80 percent, a decision was made to treat our patient with adjuvant chemotherapy. Due to her age and increased risk of cardiac toxicity with anthracycline-based chemotherapy regimens, our patient was treated with docetaxel/cyclophosphamide chemotherapy for a total of four planned cycles. However, approximately two weeks after receiving the third cycle of chemotherapy, our patient developed rapidly progressive dyspnea, and a non-productive cough and went to the emergency room at an outside medical facility. She was found to have mild hypoxemia, and new onset of peripheral, subpleural fibrotic changes not present on pre-treatment scans. A thorascopic-guided wedge biopsy of the lung tissue revealed subacute interstitial pneumonitis. Our patient made a rapid clinical recovery after treatment with corticosteroids.

Conclusions

Interstitial pneumonitis is a rare complication of docetaxel/cyclophosphamide chemotherapy that carries a high mortality rate. The only way to make a definitive diagnosis is with a wedge biopsy of the lung, which should be performed when feasible. Our patient’s case illustrates that no therapeutic intervention is without its intrinsic and unanticipated risks, and interstitial pneumonitis should be discussed as a potential side effect with all patients prior to administering docetaxel/cyclophosphamide chemotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ismael GF, Rosa DD, Mano MS, Awada A: Novel cytotoxic drugs: old challenges, new solutions. Cancer Treat Rev. 2008, 34: 81-91. 10.1016/j.ctrv.2007.08.001.CrossRefPubMed Ismael GF, Rosa DD, Mano MS, Awada A: Novel cytotoxic drugs: old challenges, new solutions. Cancer Treat Rev. 2008, 34: 81-91. 10.1016/j.ctrv.2007.08.001.CrossRefPubMed
2.
go back to reference Abeloff M: Abeloff’s Clinical Oncology. Edited by: Abeloff M. 2008, Churchill-Livingstone, Philadelphia, 4 Abeloff M: Abeloff’s Clinical Oncology. Edited by: Abeloff M. 2008, Churchill-Livingstone, Philadelphia, 4
3.
go back to reference Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009, 27: 1177-1183. 10.1200/JCO.2008.18.4028.CrossRefPubMed Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009, 27: 1177-1183. 10.1200/JCO.2008.18.4028.CrossRefPubMed
4.
go back to reference Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M: Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012, 32: 1103-1106.PubMed Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M: Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012, 32: 1103-1106.PubMed
5.
go back to reference Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ: Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean J Urol. 2012, 53: 371-374. 10.4111/kju.2012.53.5.371.CrossRefPubMedPubMedCentral Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ: Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Korean J Urol. 2012, 53: 371-374. 10.4111/kju.2012.53.5.371.CrossRefPubMedPubMedCentral
6.
go back to reference Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L: Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract. 2012, 18: 311-315. 10.1177/1078155211429384.CrossRefPubMed Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L: Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract. 2012, 18: 311-315. 10.1177/1078155211429384.CrossRefPubMed
7.
go back to reference Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y: Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother. 2010, 16: 340-344. 10.1007/s10156-010-0058-4.CrossRefPubMed Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y: Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother. 2010, 16: 340-344. 10.1007/s10156-010-0058-4.CrossRefPubMed
8.
go back to reference Kuip E, Muller E: Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med. 2009, 67: 237-239.PubMed Kuip E, Muller E: Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med. 2009, 67: 237-239.PubMed
9.
go back to reference Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW: Pneumonitis related to docetaxel: case report and review of the literature. In Vivo. 2009, 23: 635-637.PubMed Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW: Pneumonitis related to docetaxel: case report and review of the literature. In Vivo. 2009, 23: 635-637.PubMed
10.
go back to reference Prat A, Martinez P, Serrano C, Montero MA, Andreu J, Cortes J: Acute lung injury associated with docetaxel and bevacizumab. Clin Oncol (R Coll Radiol). 2007, 19: 803-805. 10.1016/j.clon.2007.08.010.CrossRef Prat A, Martinez P, Serrano C, Montero MA, Andreu J, Cortes J: Acute lung injury associated with docetaxel and bevacizumab. Clin Oncol (R Coll Radiol). 2007, 19: 803-805. 10.1016/j.clon.2007.08.010.CrossRef
11.
go back to reference Leimgruber K, Negro R, Baier S, Moser B, Resch G, Sansone S, Adami M, Zanon P, Graiff C, Egarter-Vigl E, Wiedermann CJ: Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori. 2006, 92: 542-544.PubMed Leimgruber K, Negro R, Baier S, Moser B, Resch G, Sansone S, Adami M, Zanon P, Graiff C, Egarter-Vigl E, Wiedermann CJ: Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori. 2006, 92: 542-544.PubMed
12.
go back to reference Karacan O, Eyuboglu FO, Akcay S, Ozyilkan O: Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Onkologie. 2004, 27: 563-565. 10.1159/000081339.PubMed Karacan O, Eyuboglu FO, Akcay S, Ozyilkan O: Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Onkologie. 2004, 27: 563-565. 10.1159/000081339.PubMed
13.
go back to reference Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer. 2004, 44: 363-368. 10.1016/j.lungcan.2003.12.004.CrossRefPubMed Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer. 2004, 44: 363-368. 10.1016/j.lungcan.2003.12.004.CrossRefPubMed
14.
go back to reference Behrens RJ, Gulley JL, Dahut WL: Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther. 2003, 10: 228-232. 10.1097/00045391-200305000-00011.CrossRefPubMed Behrens RJ, Gulley JL, Dahut WL: Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther. 2003, 10: 228-232. 10.1097/00045391-200305000-00011.CrossRefPubMed
15.
go back to reference Read WL, Mortimer JE, Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002, 94: 847-853. 10.1002/cncr.10263.CrossRefPubMed Read WL, Mortimer JE, Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002, 94: 847-853. 10.1002/cncr.10263.CrossRefPubMed
16.
go back to reference Wang GS, Yang KY, Perng RP: Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001, 85: 1247-1250. 10.1054/bjoc.2001.2071.CrossRefPubMedPubMedCentral Wang GS, Yang KY, Perng RP: Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001, 85: 1247-1250. 10.1054/bjoc.2001.2071.CrossRefPubMedPubMedCentral
17.
go back to reference Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T: Docetaxel and interstitial pulmonary injury. Ann Oncol. 1997, 8: 191-194. 10.1023/A:1008226416896.CrossRefPubMed Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T: Docetaxel and interstitial pulmonary injury. Ann Oncol. 1997, 8: 191-194. 10.1023/A:1008226416896.CrossRefPubMed
18.
go back to reference Mileshkin L, Prince HM, Rischin D, Zimet A: Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transpl. 2001, 27: 559-563. 10.1038/sj.bmt.1702803.CrossRef Mileshkin L, Prince HM, Rischin D, Zimet A: Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transpl. 2001, 27: 559-563. 10.1038/sj.bmt.1702803.CrossRef
19.
go back to reference Hasskarl J, Schroettner P, von den Berg A, Rueckert A, Frydrychowicz A, Kayser G, Waller CF: Severe organizing pneumonia after two cycles of docetaxel as fourth-line chemotherapy for advanced non-small cell carcinoma of the lung. Case Rep Oncol. 2009, 2: 12-19. 10.1159/000200015.CrossRefPubMedPubMedCentral Hasskarl J, Schroettner P, von den Berg A, Rueckert A, Frydrychowicz A, Kayser G, Waller CF: Severe organizing pneumonia after two cycles of docetaxel as fourth-line chemotherapy for advanced non-small cell carcinoma of the lung. Case Rep Oncol. 2009, 2: 12-19. 10.1159/000200015.CrossRefPubMedPubMedCentral
20.
go back to reference Cobo Dols M, Gil Calle S, Ales Diaz I, Villar Chamorro E, Alcaide Garcia J, Gutierrez Calderon V, Benavides Orgaz M: Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma. Clin Trans Oncol. 2006, 8: 133-135. 10.1007/s12094-006-0171-0.CrossRef Cobo Dols M, Gil Calle S, Ales Diaz I, Villar Chamorro E, Alcaide Garcia J, Gutierrez Calderon V, Benavides Orgaz M: Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma. Clin Trans Oncol. 2006, 8: 133-135. 10.1007/s12094-006-0171-0.CrossRef
21.
go back to reference Malik SW, Myers JL, DeRemee RA, Specks U: Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996, 154: 1851-1856.CrossRefPubMed Malik SW, Myers JL, DeRemee RA, Specks U: Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996, 154: 1851-1856.CrossRefPubMed
22.
go back to reference Yamada T, Sunagawa K, Homma T, Uehara K, Mizutani T, Kawabata Y: Ubiquitin-positive pneumocytes and inclusion bodies are present in secondary organizing pneumonia. Intern Med. 2011, 50: 277-283. 10.2169/internalmedicine.50.4156.CrossRefPubMed Yamada T, Sunagawa K, Homma T, Uehara K, Mizutani T, Kawabata Y: Ubiquitin-positive pneumocytes and inclusion bodies are present in secondary organizing pneumonia. Intern Med. 2011, 50: 277-283. 10.2169/internalmedicine.50.4156.CrossRefPubMed
Metadata
Title
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review
Authors
Roberto Ochoa
Pablo A Bejarano
Stefan Glück
Alberto J Montero
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2012
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-6-413

Other articles of this Issue 1/2012

Journal of Medical Case Reports 1/2012 Go to the issue